Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2005-10-18
2005-10-18
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C530S351000, C536S023500, C435S069520, C435S071100, C435S071200, C435S471000, C435S325000, C435S252300, C435S254110
Reexamination Certificate
active
06955807
ABSTRACT:
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4588585 (1986-05-01), Mark et al.
patent: 4853332 (1989-08-01), Mark et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5116943 (1992-05-01), Koths et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5229109 (1993-07-01), Grimm et al.
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 6348192 (2002-02-01), Chan et al.
patent: 0119621 (1984-09-01), None
patent: 0163249 (1985-12-01), None
patent: 0267795 (1988-05-01), None
patent: 8904665 (1989-06-01), None
patent: 9606860 (1996-03-01), None
patent: 9731622 (1997-09-01), None
patent: 9741232 (1997-11-01), None
Zurawski, S.M. and Zurawski, G., Mouse interleukin-2 structure-function studies: substitutions in the first α-helix can specificaly inactivate p70 receptor binding and mutations in the fifth α-helix can specifically inactivate p55 receptor binding, Embo.J., 8(9): 2583-2590 (1989).
Zurawski et al., Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction, Embo.J., 9(12):3899-3905 (1990).
Zurawski, G., Analysing lymphokine-receptor interactions of IL-1 and IL-2 by recombinant-DNA technology, Trends Biotech., 9: 250-257 (1991).
Zurawski S.M. and Zurawski G., Receptor antagonist and selective agonist derivatives of mouse interleukin-2, Embo.J., 11(11): 3905-3910 (1992).
Zurawski et al., Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor, Embo.J., 12(13): 5113-5119 (1993).
Théze et al., Interleukin 2 and its receptors: recent advances and new immunological functions, Immunol. Today, 17(10): 481-486 (1996).
Xu et al., Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125 Cys or 127Ser, Eur.Cytokine Netw., 6(4): 237-244 (1995)
Jacobson et al., Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity, Proc.Natl.Sci., 93: 10405-10410 (1996).
Smith K. A., Lowest Dose Interleukin-2 Immunotherapy, Blood, 81(6): 1414-1423 (1993).
Kaplan et al., Rational Immunotherapy with Interleukin 2, Biotech., 10(2): 157-162 (1992).
Buchli et al., Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog, Arch.Biochem.Biophys., 307(2): 411-415 (1993).
Cellular and Molecular Immunology, Abbas et al., eds., 1997, W.B. Saunders Company, Chapter 12, Cytokines, pp. 250-267.
Immunology, Roitt et al., eds., 1996, pp. 8.8-8.16, Fourth Edition, Mosby.
Greve Jeffrey M.
Jesmok Gary
Lembach Kenneth J.
Shanafelt Armen B.
Wetzel Gayle D.
Bayer Pharmaceuticals Corporation
Mahoney John W.
Mertz Prema
LandOfFree
IL-2 selective agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-2 selective agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-2 selective agonists and antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463976